Comparison of monotherapy with irbesartan 150 mg or amlodipine 5 mg for treatment of mild-to-moderate hypertension

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 6, Issue 2, 2005, Pages 84-89

  Neutel, Joel M ^a   Germino, F Wilford ^b   Smith, David ^a  

^a Orange County Research Center   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Ambulatory BP monitoring; Amlodipine; Irbesartan

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; IRBESARTAN; PLACEBO;

ADULT; AFRICAN AMERICAN; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ECCHYMOSIS; FEMALE; HEADACHE; HUMAN; HYPERTENSION; INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MONOTHERAPY; MULTICENTER STUDY; MYALGIA; NAUSEA; PERIPHERAL EDEMA; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SINGLE BLIND PROCEDURE; STANDARDIZATION; SYSTOLIC BLOOD PRESSURE; TREATMENT PLANNING;

EID: 28244474167     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2005.014     Document Type: Article

References (27)

1. Chobanian AV, Bakris GL, Black HR et al, and the National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42: 1206-52.
2. Levine CB, Fahrbach KR, Frame D et al. Effect of amlodipine on systolic blood pressure. Clin Ther 2003;25:35-57.
3. Haria M, Wagstaff AJ. Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease. Drugs 1995;50:560-86.
4. Norvasc® (amlodipine besylate) tablets. Prescribing information. In: Physicians Desk Reference; 2004:2615-19.
5. Eberhardt RT, Kevak RM, Kang PM, Frishman WH. Angiotensin II receptor blockade: an innovative approach to cardiovascular pharmacotherapy. J Clin Pharmacol 1993;33:1023-38.
6. Neutel JM. Safety and efficacy of angiotensin II receptor antagonists. Am J Cardiol 1999;84:13K-17K.
7. Dina R, Jafari M. Angiotensin II-receptor antagonists: an overview. Am J Health Syst Pharm 2000;57:1231-41.
8. Pylypchuk GB. ACE inhibitor- versus angiotensin II blocker-induced cough and angioedema. Ann Pharmacother 1998;32:1060-6.
9. Birkenhager WH, de Leeuw PW. Non-peptide angiotensin type 1 receptor antagonists in the treatment of hypertension. J Hypertens 1999;17:873-81.
10. Burnier M, Brunner HR. Comparative antihypertensive effects of angiotensin II receptor antagonists. J Am Soc Nephrol 1999;10(suppl 12):S278-S282.
11. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 1992;117:234-42.
12. Lacourcière Y, Brunner H, Irwin R et al and the Losartan Cough Study Group. Effects of modulators of the renin-angiotensin-aldosterone system on cough. J Hypertens 1994;12:1387-93.
13. Croom KF, Curran MP, Goa KL, Perry CM. Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy. Drugs 2004;64:999-1028.
14. Reeves RA, Lin CS, Kassler-Taub K, Pouleur H. Dose-related efficacy of irbesartan for hypertension: an integrated analysis. Hypertension 1998;31:1311-16.
15. Pool JL, Guthrie RM, Littlejohn TW, 3rd et al. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension. Am J Hypertens 1998;11:462-70.
16. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.
17. Jamerson K, DeQuattro V. The impact of ethnicity on response to antihypertensive therapy. Am J Med 1996; 101(3A):22S-32S.
18. Saunders E, Weir MR, Kong BW et al. A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med 1990;150:1707-13.
19. Cushman WC, Reda DJ, Perry HM, Williams D, Abdellatif M, Materson BJ, for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Regional and racial differences in response to antihypertensive medication use in a randomized controlled trial of men with hypertension in the United States. Arch Intern Med 2000;160:825-31.
20. Julius S, Kjeldsen SL, Weber MA et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. The Lancet. Published online June 14, 2004. http://image.thelancet.com/extras/04let5020web.pdf
21. Elmfeldt D, Olofsson B, Meredith P. The relationships between dose and antihypertensive effect of four AT1-receptor blockers. Differences in potency and efficacy. Blood Press 2002;11:293-301.
22. Oparil S, Williams D, Chrysant SG, Marbury TC, Neutel J. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens 2001;3:283-91, 318.
23. Mancia G, Korlipara K, van Rossum P, Villa G, Silvert B. An ambulatory blood pressure monitoring study of the comparative antihypertensive efficacy of two angiotensin II receptor antagonists, irbesartan and valsartan. Blood Press Monit 2002;7:135-42.
24. Kassler-Taub K, Littlejohn T, Elliott W, Ruddy T, Adler E for the Irbesartan/Losartan Study Investigators. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Am J Hypertens 1998;11:445-53.
25. Bobrie G, Giacomino A, Postel-Vinay N, Moulin C, Asmar R. COmparative Study of efficacy of Irbesartan/hydrochlorothiazide with valsartan/hydrochlorothiazide using home blood pressure Monitoring in the treAtment of mild to moderate hypertension (COSIMA). Presented at the 24th Meeting of the French Society of Arterial Hypertension, Paris, France. 16-17 December, 2004.
26. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engel J Med 2001;345:851-60.
27. American Heart Association. Heart Disease and Stroke Statistics - 2005 Update. In. Dallas, Texas: American Heart Association; 2005.